We have previously shown that pancreatic and colon cancer harboring BRCA2 alterations exhibit an extremely high sensitivity towards TNF-related apoptosis-inducing ligand (TRAIL)-targeting agents, thereby defining a previously unknown property of BRCA2 as a regulator of the sensitivity towards cell-death receptor-mediated apotosis [11]. Here, BRCA2 is linked to malignant colon neoplasm.